Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe;

doi:10.1002/art.10578

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10578 ◽

2002 ◽

Vol 46 (11) ◽

pp. 2838-2846 ◽

Cited By ~ 136

Author(s):

George Nuki ◽

Barry Bresnihan ◽

Moraye B. Bear ◽

Dorothy McCabe ◽

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Clinical Improvement ◽

Controlled Trial ◽

Interleukin 1 ◽

Extension Phase ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist

Download Full-text

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10141 ◽

2002 ◽

Vol 46 (3) ◽

pp. 614-624 ◽

Cited By ~ 403

Author(s):

Stanley Cohen ◽

Eric Hurd ◽

John Cush ◽

Michael Schiff ◽

Michael E. Weinblatt ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist

Download Full-text

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Annals of the Rheumatic Diseases ◽

10.1136/ard.2010.134254 ◽

2010 ◽

Vol 70 (5) ◽

pp. 747-754 ◽

Cited By ~ 314

Author(s):

P. Quartier ◽

F. Allantaz ◽

R. Cimaz ◽

P. Pillet ◽

C. Messiaen ◽

...

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist ◽

Systemic Onset

Download Full-text

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

JAMA ◽

10.1001/jama.271.23.1836 ◽

1994 ◽

Vol 271 (23) ◽

pp. 1836-1843 ◽

Cited By ~ 136

Author(s):

C. J. Fisher

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Sepsis Syndrome ◽

Phase Iii ◽

Study Group ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist ◽

Trial Phase

Download Full-text

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

Annals of the Rheumatic Diseases ◽

10.1136/ard.2003.016014 ◽

2004 ◽

Vol 63 (9) ◽

pp. 1062-1068 ◽

Cited By ~ 189

Author(s):

S B Cohen

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Interleukin 1 Receptor Antagonist

Download Full-text

Faculty Opinions recommendation of A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718303450.793491945 ◽

2014 ◽

Author(s):

Timothy Beukelman

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist ◽

Systemic Onset

Download Full-text

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores

Arthritis & Rheumatism ◽

10.1002/1529-0131(200005)43:5<1001::aid-anr7>3.0.co;2-p ◽

2000 ◽

Vol 43 (5) ◽

pp. 1001 ◽

Cited By ~ 252

Author(s):

Yebin Jiang ◽

Harry K. Genant ◽

Iain Watt ◽

Mark Cobby ◽

Barry Bresnihan ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Interleukin 1 ◽

Controlled Study ◽

Double Blind ◽

Interleukin 1 Receptor Antagonist ◽

Dose Ranging ◽

Radiologic Progression

Download Full-text

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10302 ◽

2002 ◽

Vol 46 (6) ◽

pp. 1451-1459 ◽

Cited By ~ 274

Author(s):

E. William St.Clair ◽

Carrie L. Wagner ◽

Adedigbo A. Fasanmade ◽

Benjamin Wang ◽

Thomas Schaible ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Improvement ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Relationship Of ◽

The Relationship

Download Full-text

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

Arthritis & Rheumatism ◽

10.1002/art.10870 ◽

2003 ◽

Vol 48 (4) ◽

pp. 927-934 ◽

Cited By ~ 226

Author(s):

Roy M. Fleischmann ◽

Joy Schechtman ◽

Ralph Bennett ◽

Malcolm L. Handel ◽

Gerd-Rudiger Burmester ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Interleukin 1 Receptor Antagonist ◽

International Multicenter

Download Full-text

The Orthokin® trial: a prospective double blind placebo-controlled randomised trial to investigate the effectiveness of autologous interleukin-1 receptor antagonist in the treatment of osteoarthritis (OA)

http://isrctn.org/> ◽

10.1186/isrctn44912979 ◽

2012 ◽

Author(s):

N.J.H. Raijmakers

Keyword(s):

Receptor Antagonist ◽

Interleukin 1 ◽

Randomised Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist

Download Full-text

Faculty Opinions recommendation of Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732271714.793540231 ◽

2017 ◽

Author(s):

Stephen Ansell

Keyword(s):

Receptor Antagonist ◽

Multicenter Study ◽

Interleukin 1 ◽

Interleukin 1 Receptor Antagonist ◽

Schnitzler’S Syndrome

Download Full-text